Welcome to our dedicated page for Firefly Neuroscience news (Ticker: AIFF), a resource for investors and traders seeking the latest updates and insights on Firefly Neuroscience stock.
Firefly Neuroscience Inc. (NASDAQ: AIFF) is a pioneer in AI-powered brain health diagnostics, leveraging its FDA-cleared Brain Network Analytics™ platform to transform neurological care. This page serves as the definitive source for official company updates, providing stakeholders with timely insights into clinical advancements and strategic initiatives.
Access verified information on AIFF's neurotechnology developments, including new research partnerships, regulatory milestones, and innovations in EEG-based diagnostics. Our curated news collection covers essential updates across four key areas: product enhancements to the BNA™ platform, clinical trial collaborations with pharmaceutical leaders, peer-reviewed study findings, and operational developments impacting neurological care delivery.
Investors and healthcare professionals rely on this resource for accurate reporting on AIFF's patented machine learning algorithms and their applications in treating cognitive disorders. All content undergoes strict verification to ensure compliance with financial disclosure standards and medical reporting best practices.
Bookmark this page for direct access to Firefly Neuroscience's latest progress in translating complex brain data into actionable clinical insights through artificial intelligence. Regularly updated to reflect the company's role in advancing precision neurology.
Hemostemix (TSXV: HEM) and Firefly Neuroscience (NASDAQ: AIFF) have announced a collaboration to conduct a Phase 1 clinical trial studying ACP-01 as a treatment for vascular dementia. The trial will evaluate brain wave activity in up to 100 patients using Firefly's FDA-Cleared BNA™ platform.
The study will assess patients before treatment and at 3 and 6-month intervals post-treatment. Hemostemix will leverage Firefly's database of 77,000 EEG brain scans across twelve disorders. The trial's primary endpoints include safety assessment, ACP-01 delivery feasibility via intrathecal injection, dosage safety, and tolerability.
Secondary endpoints encompass cognitive functional assessment, clinical dementia rating, quality of life assessment, and MRI analyses of brain volume and blood flow. The exploratory endpoint will use Firefly's BNA™ readout at specified intervals to objectively evaluate ACP-01's efficacy in treating vascular dementia.
Firefly Neuroscience (NASDAQ: AIFF) has received $8.8 million from the exercise of warrants, significantly strengthening its cash position through mid-2026. The proceeds came from two warrant exercises: 823,530 shares at $6.83 and 800,000 shares at $4.00, originally issued in private placements from August and December 2024. No new warrants were issued as part of these exercises.
The funds will support general working capital needs, including Firefly's initiative to develop the world's first foundation model of the human brain using their FDA-cleared Brain Network Analytics (BNA™) technology platform. The company focuses on developing AI solutions for improving brain health outcomes in patients with neurological and mental disorders.
Firefly Neuroscience (NASDAQ: AIFF) has been accepted into the NVIDIA Connect program, marking a significant development for the AI-focused neuroscience company. The company plans to leverage NVIDIA's resources to build the world's first foundation model of the human brain using its FDA-cleared Brain Network Analytics (BNA™) technology platform, which utilizes Resting EEG and Cognitive EEG data.
The NVIDIA Connect program will provide Firefly with advanced software development resources, industry-leading frameworks, software development kits, technical training, engineering guidance, and discounts on NVIDIA software and hardware. Executive Chairman Greg Lipschitz highlighted this as an important milestone, noting that Firefly's growing BNA™ database, combined with NVIDIA's resources, positions the company uniquely for this ambitious project.
Firefly Neuroscience (NASDAQ: AIFF) announces that Dr. Christopher Wilson, a member of their Advisory Development Board, has received the Faculty Research Excellence Award from the University of Waterloo's Faculty of Engineering. Dr. Wilson, who works at the Institute for Quantum Computing (IQC), specializes in superconducting quantum electronics research.
Dr. Wilson has secured $13 million in research funding throughout his career from various international agencies. His achievements include supervising over 40 researchers, publishing more than 100 refereed publications, and co-authoring a new textbook titled 'Building Quantum Computers' published by Cambridge University Press in 2024.
The company mentions that Dr. Wilson is currently involved in a new brain model initiative at Firefly, with more details to be announced in the future.
Firefly Neuroscience (NASDAQ: AIFF) has announced two significant studies demonstrating the effectiveness of their FDA-cleared BNA™ platform in drug development and neuropsychiatric care through advanced EEG analytics. The first study, conducted with Novartis, examined MIJ821's effects, showing dose-dependent EEG changes and validating EEG as a pharmacokinetic-pharmacodynamic tool.
The second study focused on Major Depressive Disorder (MDD) treatment, revealing that baseline brain activation latencies measured through BNA™ technology were longer in MDD patients compared to controls, but normalized after treatment. This demonstrated improved cognitive functioning independent of antidepressant effects.
The research validates BNA™'s capability to provide objective measures of treatment efficacy and cognitive change, supporting its potential role in advancing personalized psychiatry and drug development.
Firefly Neuroscience (NASDAQ: AIFF) has announced a significant breakthrough in brain age assessment using its FDA-cleared BNA™ technology platform. The company has developed a method to estimate biological brain age using Resting EEG and Cognitive EEG (ERP) data, marking the first successful use of cognitive ERP data for brain age assessment.
The technology can identify significant disparities between brain age and chronological age, which could serve as a potential risk factor for dementia. This breakthrough represents a potential advancement in early screening and monitoring capabilities for Alzheimer's patients, offering a proactive and scalable approach to brain health assessment.
The research findings were presented at AD/PD 2024, demonstrating the platform's innovative capabilities to researchers and clinicians in the field of neurological disorders.
Arrivo BioVentures reported positive results from its SP-624-103 study evaluating SP-624's impact on neurological pathways. The double-blind, placebo-controlled study's first cohort, comprising 12 healthy subjects, showed significant brain activity changes after a single 20mg dose. Key findings include increased beta power in frontal-central regions and decreased delta power, suggesting enhanced neural synchronization and cortical activation.
The study utilized Firefly Neuroscience's (NASDAQ: AIFF) brain network analytics (BNA™) and qEEG assessments. SP-624, a SIRT6 activator, demonstrated potential for treating females with Major Depression. The company is currently conducting a Phase 2b/3 study for major depressive disorder, with Cohort 2 actively enrolling 12 MDD patients.
Firefly Neuroscience (NASDAQ: AIFF) has secured financing of up to $12.4 million, comprising $2.4 million in senior secured convertible notes at $3.00 per share and a $10 million equity line of credit. The AI company, which develops solutions for neurological and mental disorders, will use the proceeds to support growth initiatives and commercialize its FDA-510(k) cleared Brain Network Analytics (BNA™) technology. The funding will accelerate two strategic commercialization pathways: partnering with neuroscience pharmaceutical companies and supporting US neurologists and psychiatrists in patient care optimization.
Firefly Neuroscience (NASDAQ: AIFF) has appointed current board member Greg Lipschitz as Executive Chairman, effective December 3, 2024. Lipschitz, who has served as director since December 2022, brings over 13 years of experience in private equity, merchant banking, capital markets, and finance. He previously served as Vice President of Lazer Capital and currently serves as Managing Director of Old Stone Advisors. The appointment comes as the company prepares to commercialize its AI technology for brain health solutions.
Former Executive Chairman David Johnson has resigned from the board effective November 30, 2024, with no disagreements reported regarding company operations, policies, or practices.
Firefly Neuroscience (NASDAQ: AIFF), an AI company focused on brain health solutions, reported its Q3 2024 results and strategic updates. The company has successfully established partnerships with major pharmaceutical companies including Bright Minds Bioscience, Novartis, and Takeda to advance its FDA-cleared Brain Network Analytics (BNA™) technology. Firefly is pursuing a dual strategy: supporting US neurologists in patient care and collaborating with pharmaceutical companies for drug development. The company leverages a proprietary database of over 77,000 EEG scans across twelve disorders. As of September 30, 2024, Firefly reported cash holdings of $1.2 million and 8,503,365 outstanding shares as of November 12, 2024.
FAQ
What is the current stock price of Firefly Neuroscience (AIFF)?
What is the market cap of Firefly Neuroscience (AIFF)?
